Pan-cancer analysis identifies PD-L2 as a tumor promotor in the tumor microenvironment

Abstract

BackgroundProgrammed cell death protein 1 (PD-1) receptor has two ligands,programmed death-ligand 1 (PD-L1) and PD-L2. When compared with PD-L1, PD-L2 has not received much attention, and its role remains unclear.MethodsThe expression profiles of pdcd1lg2 (PD-L2-encoding gene) mRNA and PD-L2 protein were analyzed using TCGA, ICGC, and HPA databases. Kaplan-Meier and Cox regression analyses were used to assess the prognostic significance of PD-L2. We used GSEA, Spearman’s correlation analysis and PPI network to explore the biological functions of PD-L2. PD-L2-associated immune cell infiltration was evaluated using the ESTIMATE algorithm and TIMER 2.0. The expressions of PD-L2 in tumor-associated macrophages (TAMs) in human colon cancer samples, and in mice in an immunocompetent syngeneic setting were verified using scRNA-seq datasets, multiplex immunofluorescence staining, and flow cytometry. After fluorescence-activated cell sorting, flow cytometry and qRT-PCR and transwell and colony formation assays were used to evaluate the phenotype and functions of PD-L2+TAMs. Immune checkpoint inhibitors (ICIs) therapy prediction analysis was performed using TIDE and TISMO. Last, a series of targeted small-molecule drugs with promising therapeutic effects were predicted using the GSCA platform.ResultsPD-L2 was expressed in all the common human cancer types and deteriorated outcomes in multiple cancers. PPI network and Spearman’s correlation analysis revealed that PD-L2 was closely associated with many immune molecules. Moreover, both GSEA results of KEGG pathways and GSEA results for Reactome analysis indicated that PD-L2 expression played an important role in cancer immune response. Further analysis showed that PD-L2 expression was strongly associated with the infiltration of immune cells in tumor tissue in almost all cancer types, among which macrophages were the most positively associated with PD-L2 in colon cancer. According to the results mentioned above, we verified the expression of PD-L2 in TAMs in colon cancer and found that PD-L2+TAMs population was not static. Additionally, PD-L2+TAMs exhibited protumor M2 phenotype and increased the migration, invasion, and proliferative capacity of colon cancer cells. Furthermore, PD-L2 had a substantial predictive value for ICIs therapy cohorts.ConclusionPD-L2 in the TME, especially expressed on TAMs, could be applied as a potential therapeutic target.

An anoikis-related gene signature predicts prognosis, drug sensitivity, and immune microenvironment in cholangiocarcinoma

“…It was demonstrated that inhibiting the LGALS9 /Tim-3 pathway elicits anti-tumor immune responses and hampers the development of tumors [ 57 ]. Additionally, it has been indicated that binding of PDCD1LG2 to PD-1 significantly inhibits T cell receptor-mediated proliferation and cytokine production by T cells [ 58 ]. Tanegashima et al [ 59 ] indicated that the expression of PDCD1LG2 in tumor cells played a crucial role in evading anti-tumor immunity.…”

Construction and Validation of a Reliable Disulfidptosis-Related LncRNAs Signature of the Subtype, Prognostic, and Immune Landscape in Colon Cancer

“…TMB demonstrates a strong correlation with tumor immune response and prognosis. Previous studies have reported that TMB can predict the response to ICI in metastatic colorectal cancer patients with high microsatellite instability (MSI-high) [ 39 ]. Despite the lack of a substantial statistical disparity in TMB between the high- and low-risk cohorts within our investigation, patients presenting both elevated TMB and high-risk factors demonstrated the most unfavorable prognosis when contrasted with the remaining patient populations.…”

Programmed cell death-ligand 2: new insights in cancer

“…Because the affinity of PD-1 to PD-L1 and PD-1 to PD-L2 is quite different. These small molecules hold the potential to penetrate the tumor microenvironment more effectively than traditional anti-PD-1/PD-L1 axis drugs, such as pabolizumab, potentially enhancing therapeutic efficacy ( 80 ). One notable molecular targeted drug in this context is JQ1, a BET-bromine domain inhibitor.…”